In a major advancement in the fight against antibiotic-resistant infections, the U.S. Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The approval provides patients and healthcare providers with a long-awaited oral alternative to intravenous carbapenem therapy.
Complicated urinary tract infections affect millions of people each year and are often associated with underlying medical conditions, urinary tract abnormalities, or infections caused by multidrug-resistant bacteria. Many of these cases require hospitalization because the most effective antibiotics, known as carbapenems, have traditionally been available only through intravenous administration.
The newly approved medicine, developed by GSK, changes this treatment landscape by allowing patients to receive carbapenem therapy orally. Experts believe the availability of an oral option could help reduce hospital stays, facilitate earlier patient discharge, and decrease the need for outpatient intravenous antibiotic administration.
Tebipenem pivoxil hydrobromide belongs to the carbapenem class of antibiotics, which are considered among the most powerful treatments for serious infections caused by resistant Gram-negative bacteria. Until now, no oral carbapenem had been approved in the United States for adult patients, making this authorization a historic milestone in infectious disease management.
The FDA's decision was supported by positive results from the Phase III PIVOT-PO clinical trial involving 1,690 hospitalized adults with complicated urinary tract infections and acute pyelonephritis. The study demonstrated that oral tebipenem was as effective as intravenous imipenem-cilastatin, a widely used standard-of-care antibiotic regimen. The trial was stopped early after an independent review found strong evidence of efficacy.
Earlier studies had also shown that oral tebipenem achieved clinical outcomes comparable to intravenous carbapenem therapy while maintaining a similar safety profile. Commonly reported side effects included diarrhea and headache, with no major new safety concerns identified during development.
Healthcare professionals view the approval as an important step toward improving treatment access for patients with drug-resistant urinary tract infections. By offering an effective oral therapy, Utebzi may help reduce healthcare costs, minimize hospitalization requirements, and provide greater convenience for patients who would otherwise need prolonged intravenous treatment.
GSK has indicated that the medicine is expected to become available to patients in the United States by the end of 2026. The approval also strengthens the company's growing portfolio of anti-infective medicines aimed at addressing the global challenge of antimicrobial resistance.
